Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells
Authors:
- 1 October 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 11 (4) , 717-722
Abstract
Background: Chemotherapeutic resistance is a main problem in clinical breast cancer therapy. The purpose of our study is to investigate whether the combination of neoadjuvant chemotherapy and survivin siRNA treatment could enhance the therapeutic effect of neoadjuvant chemotherapy using paclitaxel or epirubicin. Materials and Methods: The molecular cloning technique was applied to construct the expression vector of siRNA against survivin. Effectene Transfection Reagent was used to transfect plasmids to MCF-7 cells. Survivin expressions were detected by quantitative real-time PCR (qRT-PCR) and Western blot methods. The effect of paclitaxel or epirubicin, with or without the combination of survivin siRNA treatment, on drug susceptibility of MCF-7 cells was detected by CCK-8 assay. MCF-7 cell apoptosis was detected by Flow Cytometry. Results: Survivin siRNA effectively inhibited the expression of Survivin RNA and protein levels (P < 0.05). Both paclitaxel and epirubicin can suppress the proliferation of MCF-7 cells and induce apoptosis to a certain degree respectively. The combination of survivin siRNA with the two chemotherapy drugs significantly enhanced both effects of the two chemotherapeutics respectively (P < 0.05). Conclusion: Survivin siRNA combined with the neoadjuvant chemotherapy can significantly enhance the sensitivity of MCF-7 cells to chemotherapeutics and cell apoptosis. This technology has important potential value in the therapeutic study of breast cancer.Keywords
This publication has 22 references indexed in Scilit:
- Neoadjuvant therapy for breast cancerJournal of Surgical Oncology, 2010
- In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cellsCancer Chemotherapy and Pharmacology, 2009
- Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell linesToxicology and Applied Pharmacology, 2009
- Neoadjuvant therapy for breast cancer: Assessing treatment progress and managing poor respondersCurrent Oncology Reports, 2008
- Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast CancerWorld Journal of Surgery, 2008
- Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cellsBreast Cancer Research and Treatment, 2008
- Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cellsBreast Cancer Research and Treatment, 2008
- The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profileEuropean Journal of Cancer, 2004
- Pathobiology of preoperative chemotherapyCancer, 2002
- Structural Basis for the Inhibition of Caspase-3 by XIAPCell, 2001